Impact of gastrectomy on efficacy and safety of second‐line chemotherapy patients with advanced gastric cancer: Exploratory analysis of two randomized phase <scp>III</scp> trials
Patients with previous gastrectomy are expected to have better survival outcomes when receiving second-line irinotecan (IRI)-based chemotherapy for AGC.
Authors
- Toshimasa Tsujinaka (ORCID: https://orcid.org/0000-0002-0893-6570)
- Yusuke Akamaru
- Akira Tsuburaya (ORCID: https://orcid.org/0000-0002-7931-8171)
- Hisashi Hosaka
- Takaki Yoshikawa (ORCID: https://orcid.org/0000-0003-1936-9484)
- Wasaburo Koizumi (ORCID: https://orcid.org/0000-0001-9972-1083)
- Kazuhiro Nishikawa (ORCID: https://orcid.org/0000-0003-1213-2732)
- Junichi Sakamoto (ORCID: https://orcid.org/0000-0002-4316-0763)
- Satoshi Morita (ORCID: https://orcid.org/0000-0002-4344-3317)
- Ken Nishimura
- Ken Shimada
- Kazumasa Fujitani
- Motoko Suzuki
Institutions
- Kyoto University (JP)
- Osaka Prefectural Medical Center (JP)
- Kitasato University Hospital (JP)
- Osaka Rosai Hospital (JP)
- Izumi City General Hospital (JP)
- National Cancer Center Hospital East (JP)
- Tokai Central Hospital (JP)
- Kitasato Institute Hospital (JP)
- Tokyo National Hospital (JP)
- SHOWA Medical University Hospital (JP)
- Hyogo Prefectural Cancer Center (JP)
- Kitasato University (JP)
Publication Details
- Journal
- Annals of Gastroenterological Surgery
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1002/ags3.12880
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00